header logo image


Page 351«..1020..350351352353..360370..»

Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and…

October 6th, 2020 4:52 am

New York, NY Aqua-Spark(the Fund), the first investment fund focused on sustainable aquaculture, announced an investment inShiok Meats(Shiok), the worlds first cell-based crustacean meat company based in Singapore. Shiok is the first cell-based meat company in South East Asia, and the first and only cell-based meat company working on shrimp. Their flagship product is a highly-anticipated cell-based shrimp, which offers clean, traceable alternatives to the shrimp farming industry.

Aqua-Spark is the lead investor in Shiok Meats $12.6M Series A round, which also includes investments from SEEDS Capital (the investment arm of Enterprise Singapore), Real Tech Fund (Japan), Irongrey (a Global tech investing family office based in Korea), Yellowdog Empowers Fund (South Korea), Ilshin Holdings Pte. Ltd (Singapore), Toyo Seikan Group Holdings, Ltd (Japan),Veg Invest Trust (USA), Makana Ventures (Singapore), AiiM Partners LP (USA), Beyond Impact (Europe), Kelvin Chan Siang Lin (Singapore), and Alex Payne and Nicole Brodeur (USA). The funds will contribute towards building the first-of-its-kind commercial pilot plant from which Shiok plans to launch its minced shrimp product in 2022. This puts Shiok on schedule to become the first company in the world to have a fully functioning commercial pilot plant for cell-based crustacean production.

Mike Velings and Amy Novogratz, co-founders of Aqua-Spark:

The cell-based animal protein industry has been on our radar for some time as once it is at scale it will have an enormous influence on food production efficiency, food safety, and the environment. As our first investment in cell-based seafood, Shiok Meats immediately stood out to us with their strong, female-led team and impressive milestones to-date. While weve invested in a number of technologies working to make shrimp farming more efficient, healthier, and less polluting, Shiok is the first company in our portfolio to focus on shrimp production. We are excited to help shape this novel and innovative industry, which we expect to have a huge impact on the future of seafood, while continuing to support sustainable aquaculture operations, inputs, and innovations across the value chain.

The shrimp market is a $50 billion market globally with Vietnam, Thailand, Indonesia, and India being the major producers of shrimp. While there are many farms and technologies improving shrimp farming, there is still work to be done. Much of what is currently on the market is raised in crowded factories/farms and treated with antibiotics, chemicals, and hormones. Conventional production processes often contribute to overfishing, excessive bycatch, misrepresentation, and mislabeling as well as contamination with effluents, heavy metals, and microplastics. This form of production is unsustainable and the sector strain will only increase as the population grows. Shiok is addressing this need and disrupting crustacean production to ensure people can eat clean shrimp, crab and lobster from a safe source. Clean meat production could reduce the industrys greenhouse gas emissions by 96 percent, energy consumption by 45 percent, land use by 99 percent, and water consumption by 96 percent.

Shiok Meats was founded in August 2018 by two stem cell scientists, Dr. Sandhya Sriram and Dr. Ka Yi Ling, with over 20 years of combined experience in the muscle, fat, and stem cell biology fields. Shioks mission is to produce clean, healthy, cruelty-free seafood. Their cell-based production process is non-GMO and chemical and antibiotic-free.

Dr. Sandhya Sriram, CEO and co-founder of Shiok Meats:

We are extremely excited to work in partnership with Aqua-Spark as we develop cell-based seafood and meats that are contributing towards a cleaner and healthier seafood industry and solving for the inefficiencies around global protein production. Aqua-Spark was the perfect partner to lead our Series A because they care deeply about funding companies that address planetary health and food security. With their help, we hope to become the global leader in cell-based crustaceans and seafood. We are pleased that Aqua-Spark supports our global impact vision and will be with us for the long haul.

Shiok stands out from other cell-based meat production companies because of their proprietary technology that isolates stem cells from shrimp, lobster, and crabthey are the first company to be able to do this for cell-based production at the moment. Once the stem cells are harvested, the shrimp, lobster, and crab meats are grown in nutrient-rich conditions, similar to that of a greenhouse. After four-to-six weeks, the cell-based seafood is exactly the same as its conventional counterpart but more sustainable, clean, and nutritious. Shioks patent-pending technology can grow crustaceans four times faster than conventional production.

The output of Shioks pilot plant will be frozen cell-based shrimp meat for dumplings and other shrimp-based dishes. Beyond cell-based shrimp, Shiok plans to launch shrimp flavouring paste and powder, fully-formed 3D shrimp, and cell-based lobster and crab products in the coming years.

To date, Aqua-Spark has now invested in 20 complementary companies, technologies, and inputs that are working toward the sustainable production of aquatic life.

About Aqua-Spark

Launched in 2011, Aqua-Spark is an investment fund with a mission to transform the global aquaculture industry into one that is healthier, more sustainable, and more accessible. They invest in aquaculture companies across the value chainspanning farming operations, alternative feed ingredients, disease-battling technology, and consumer-facing aquaculture products. These companies are solving some of the industrys big challenges while bringing returns that are comparable to todays traditional industry. The portfolio works as an ecosystem, with the companies agreeing to collaborate on optimal solutions, and working together toward this shared vision of a more efficient global aquaculture industry.

Since 2015, the fund has invested in 20 complementary SMEs. Thus far, Aqua-Spark has EUR 152 million in assets under management, dedicated to investments in elements of the aquaculture industry that will make fish farming sustainable. The goal of the fund is to ultimately make sustainability widespread and profitable enough that it becomes the only way to farm fish.

About Shiok Meats

Shiok Meats is a cell-based, clean meat company. It is the first of its kind in Singapore and South-East Asia with a mission to deliver delicious, clean, and healthy seafood by harvesting from cells instead of animals. Shiok Meats is working to bring cell-based crustacean meats (shrimp, crab, lobster) to the kitchen. Their meats are cruelty-free, healthy, and better for the environment with the same taste and texture and more nutrients than their traditional counterparts.

Go here to see the original:
Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and...

Read More...

Is Kaleido Biosciences Inc (KLDO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

October 4th, 2020 11:01 am

Kaleido Biosciences Inc (KLDO) is around the top of the Biotechnology industry according to InvestorsObserver. KLDO received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Kaleido Biosciences Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 34 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Kaleido Biosciences Inc (KLDO) stock is lower by -2.62% while the S&P 500 is up 0.6% as of 1:15 PM on Thursday, Oct 1. KLDO is down -$0.29 from the previous closing price of $11.07 on volume of 311,178 shares. Over the past year the S&P 500 has risen 17.16% while KLDO is up 49.72%. KLDO lost -$2.62 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Kaleido Biosciences Inc (KLDO) Stock.

The rest is here:
Is Kaleido Biosciences Inc (KLDO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Global Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2026 – The…

October 4th, 2020 11:01 am

The latest report titled Global Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Status and Forecast 2020-2026 aims to enhance your decision-making ability in the business by providing knowledgeable insights related to the market and competitive landscape. The report recognizes vital facts, events, and possible variations in the global Nanoparticles in Biotechnology and Pharmaceuticals market. The report depicts valuable insights related to significant market trends driving the industry. It highlights key opportunities and challenges faced by market leaders while assessing their competitive setting and corporate strategies for the estimated timeline. The report also reveals drivers, trends, the market scope, profitability, demand status, uncertainties, and development forecast from 2020 to 2026 time-period.

The report covers SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. The research studies the global Nanoparticles in Biotechnology and Pharmaceuticals market competition, leading companies, industry environment, emerging opportunities, trends, and crucial segments in the market. Then the study encompasses company profiles, size, production value, product specifications, capacity, and 2020-2026 market shares occupied by each company. The global market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/23602/request-sample

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Key Segments Studied In The Report:

For competitor segment, the report includes global key players of the market as well as some small players: Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire,

Segment by product type, this report focuses on consumption, market share, and growth rate of the market in each product type and can be divided into:

Segment by application, this report focuses on consumption, market share, and growth rate of the market in each application and can be divided into: Biotechnology, Pharmaceutical,

The important geographical segments of the global Nanoparticles in Biotechnology and Pharmaceuticals market are as follows: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa).

Production and consumption Analysis of The Global Nanoparticles in Biotechnology and Pharmaceuticals Market:

One part is about its production and the other part is about its consumption. On the basis of its production, the report analyzes the production, revenue, gross margin of its main manufacturers, and the unit price that they offer in different regions from 2015 to 2019. In terms of consumption, we analyze the consumption volume, consumption value, sale price, import, and export in different regions from 2015 to 2019. We also make a prediction of its production and consumption in the coming 2020-2026.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanoparticles-in-biotechnology-and-pharmaceuticals-market-size-23602.html

Key Report Pointers & Highlights:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

See the original post:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2026 - The...

Read More...

Is Abeona Therapeutics Inc (ABEO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

October 4th, 2020 11:01 am

Abeona Therapeutics Inc (ABEO) is around the bottom of the Biotechnology industry according to InvestorsObserver. ABEO received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Abeona Therapeutics Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Abeona Therapeutics Inc (ABEO) stock has fallen -5.46% while the S&P 500 is up 1.25% as of 2:03 PM on Wednesday, Sep 30. ABEO is down -$0.06 from the previous closing price of $1.11 on volume of 4,933,979 shares. Over the past year the S&P 500 is higher by 14.86% while ABEO is down -53.95%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

More:
Is Abeona Therapeutics Inc (ABEO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated…

October 4th, 2020 11:00 am

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the companys previously reported Phase 1 trial of PDS0101 and planned Phase 2 clinical studies in patients with advanced HPV-associated malignancies at the World Vaccine Congress, being held virtually September 28 October 1, 2020.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotechs filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

James SaliernoThe Ruth GroupPhone: +1 (646) 536-7028 / +1 (973) 255-8361Email: jsalierno@theruthgroup.com

The rest is here:
PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated...

Read More...

Is Seelos Therapeutics Inc (SEEL) a Winner in the Biotechnology Industry? – InvestorsObserver

October 4th, 2020 11:00 am

The 65 rating InvestorsObserver gives to Seelos Therapeutics Inc (SEEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, SEELs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Seelos Therapeutics Inc (SEEL) stock is lower by -6.62% while the S&P 500 has risen 1.25% as of 1:21 PM on Wednesday, Sep 30. SEEL is lower by -$0.07 from the previous closing price of $1.04 on volume of 6,319,446 shares. Over the past year the S&P 500 has gained 14.86% while SEEL has risen 7.78%. SEEL lost -$0.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Seelos Therapeutics Inc (SEEL) Stock.

View post:
Is Seelos Therapeutics Inc (SEEL) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Microbioreactor System Market 2020: What Are The New Innovations By Companies- Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR,…

October 4th, 2020 11:00 am

Reports from Quince Market Insights adds to its database of reports of Global Microbioreactor System Market Share, Growth, Trends, and Expected Market Research Study. This report provides a strategic overview of the Global Microbioreactor System Market and the forecasted growth estimates for the future. The main purpose of this report is to help the consumer understand the market as a whole, its meanings and segmentation, market potential, influential trends, and the barriers that it is facing. The Global Microbioreactor System Market report points out national and global business prospects and competitive conditions for Microbioreactor System .

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-66040?utm_source=Arshad/dc

Companies Covered: Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR, M2p-labs, INFORS HT, PBS Biotech, Sysbiotech, HiTec Zang

Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Global Microbioreactor System . The Global Microbioreactor System Market has been segmented : By Type (24 Parallel Bioreactors, 48 Parallel Bioreactors, Others), By Application (Pharma, Biotech, Food Industry, Scientific Research Institutes, Others). Strict research and review have been a significant part of the preparation of the study. Those who read the report will get a thorough understanding of the industry.

Microbioreactor System Market

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-66040?utm_source=Arshad/dc

Industry experts have reviewed and validated the data and information taken from reputable sources such as blogs, business annual reports, journals, and other documents. To offer a detailed picture of the facts and data, diagrams, graphs, pie charts, and other representations have been used. This augments the visual appeal of the report and makes it easier to understand. Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, and South America.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-66040?utm_source=Arshad/dc

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more:
Microbioreactor System Market 2020: What Are The New Innovations By Companies- Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR,...

Read More...

Agricultural Biotechnology Market 2020: by Region, Production, Consumption, Revenue, Market Share, Growth Rate Analysis and Forecast Till 2025 – The…

October 4th, 2020 11:00 am

Agricultural Biotechnology Market report puts across the idea of high-level analysis of major market segments and identification of opportunities. This information not only aids businesses in taking sound and proficient decisions but also helps decide the advertising, promotion, marketing and sales strategy more gainfully. Moreover, estimation of strategic options, suggestions of winning action plans and support to make critical bottom-line decisions is also provided by experienced and innovative industry experts. It supports in adjusting the production depending on the conditions of demand in the market which evades the wastage of goods. The market data analysed in this Agricultural Biotechnology Market report makes achieve the business goal and objective in predetermined time frame.

Few of the major competitors currently working in the global Agricultural Biotechnology market are:

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Get Free Sample Report @ https://www.adroitmarketresearch.com/contacts/request-sample/113

A large-scale Agricultural Biotechnology Market report is of great importance for better understanding of the market which leads to high business growth. This market report has a chapter on the global market and all its associated companies with their profiles, which gives valuable data related to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. Agricultural Biotechnology Market research report provides important and meaningful market insights for the business by taking into consideration various factors. Thoroughly analysed market segmentation aspect provides a clear idea about the product consumption based on several factors ranging from type, application, deployment model, end user to geographical region.

Global Agricultural Biotechnology market is set to witness a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the surging adoption of AI and IoT along with the involvement of Agricultural Biotechnology vendors

Regional Analysis Includes:

*Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)*Europe (Germany, France, UK, Russia, and Italy etc.)*North America (the United States, Mexico, and Canada.)*South America (Brazil, Argentina, Columbia, etc.)*The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Table and Figures Covered in This Report:*Agricultural Biotechnology Market Overview, Scope, Status, and Prospect*Agricultural Biotechnology Market Competition by Manufacturers*Agricultural Biotechnology Market Capacity, Production, Revenue (Value) by Region*Agricultural Biotechnology Market Supply (Production), Consumption, Export, Import by Region*Agricultural Biotechnology Market Production, Revenue (Value), Price Trend by Type*Agricultural Biotechnology Market Analysis by Application*Agricultural Biotechnology Market Manufacturing Cost Analysis*Agricultural Biotechnology Market Industry Effect Factors Analysis*Agricultural Biotechnology Market Forecast*Agricultural Biotechnology Market Research Findings and Conclusion

Access Detailed Report at https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

What are the Recent Development of the Market?

Agricultural Biotechnology Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Agricultural Biotechnology Market.

Key Questions Answered:

*What is the size and CAGR of the global Agricultural Biotechnology Market?*What are the key driving factors of the most profitable regional market?*Which are the leading segments of the global market?*How will the global market advance in the coming years?*What are the main strategies adopted in the global market?*What is the nature of competition in the global market?*What growth impetus or acceleration market carries during the forecast period?*Which region may hit the highest market share in the coming era?*What trends, challenges, and barriers will impact the development and sizing of the market?

Still Any Query? Feel Free to Contact our Expert at https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Agricultural Biotechnology Market 2020: by Region, Production, Consumption, Revenue, Market Share, Growth Rate Analysis and Forecast Till 2025 - The...

Read More...

Interferon Market Growth, Projections, Analysis, Trends and Forecast 2026 | ( Roche, Anke Biotechnology, Bayer) – The Daily Chronicle

October 4th, 2020 11:00 am

LOS ANGELES, United States:The report is an all-inclusive research study of the global Interferon market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Interferon market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Interferon report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.qyresearch.com/sample-form/form/1638467/global-interferon-market

In addition, market revenues based on region and country are provided in the Interferon report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Interferon market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Interferon market are mapped by the report. With the help of this report, the key players of the global Interferon market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Interferon market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Interferon market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Interferon Market Research Report: Roche, Anke Biotechnology, Bayer, Merck & Co, Tri-Prime, Kawin, Genzon Pharma, Novartis, Biogen, Merck KGaA, Zydus Cadila, Huaxin Biotechnology, Harbin Pharmaceutical

Global Interferon Market Segmentation by Product: Assay Kit, Analyzer

Global Interferon Market Segmentation by Application: , Hepatitis, Multiple Sclerosis, Others

The Interferon Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Interferon market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Interferon market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1638467/global-interferon-market

Table of Contents:

1 Interferon Market Overview1.1 Interferon Product Overview1.2 Interferon Market Segment by Type1.2.1 Long-lasting Type1.2.2 Ordinary Type1.3 Global Interferon Market Size by Type (2015-2026)1.3.1 Global Interferon Market Size Overview by Type (2015-2026)1.3.2 Global Interferon Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Interferon Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Interferon Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Interferon Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Interferon Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Interferon Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Interferon Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Interferon Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Interferon Sales Breakdown by Type (2015-2026)1.4.2 Europe Interferon Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Interferon Sales Breakdown by Type (2015-2026)1.4.4 Latin America Interferon Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Interferon Sales Breakdown by Type (2015-2026)1.5 Coronavirus Disease 2019 (Covid-19): Interferon Industry Impact1.5.1 How the Covid-19 is Affecting the Interferon Industry

1.5.1.1 Interferon Business Impact Assessment Covid-19

1.5.1.2 Supply Chain Challenges

1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Interferon Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-19

1.5.3.1 Government Measures to Combat Covid-19 Impact

1.5.3.2 Proposal for Interferon Players to Combat Covid-19 Impact 2 Global Interferon Market Competition by Company2.1 Global Top Players by Interferon Sales (2015-2020)2.2 Global Top Players by Interferon Revenue (2015-2020)2.3 Global Top Players Interferon Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Interferon Manufacturing Base Distribution, Sales Area, Product Type2.5 Interferon Market Competitive Situation and Trends2.5.1 Interferon Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Interferon Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Interferon as of 2019)2.7 Date of Key Manufacturers Enter into Interferon Market2.8 Key Manufacturers Interferon Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Interferon Status and Outlook by Region (2015-2026)3.1 Global Interferon Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Interferon Market Size Market Share by Region (2015-2020)3.2.1 Global Interferon Sales Market Share by Region (2015-2020)3.2.2 Global Interferon Revenue Market Share by Region (2015-2020)3.2.3 Global Interferon Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Interferon Market Size Market Share by Region (2021-2026)3.3.1 Global Interferon Sales Market Share by Region (2021-2026)3.3.2 Global Interferon Revenue Market Share by Region (2021-2026)3.3.3 Global Interferon Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Interferon Market Size YoY Growth (2015-2026)3.4.1 North America Interferon Revenue YoY Growth (2015-2026)3.4.2 North America Interferon Sales YoY Growth (2015-2026)3.5 Asia-Pacific Interferon Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Interferon Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Interferon Sales YoY Growth (2015-2026)3.6 Europe Interferon Market Size YoY Growth (2015-2026)3.6.1 Europe Interferon Revenue YoY Growth (2015-2026)3.6.2 Europe Interferon Sales YoY Growth (2015-2026)3.7 Latin America Interferon Market Size YoY Growth (2015-2026)3.7.1 Latin America Interferon Revenue YoY Growth (2015-2026)3.7.2 Latin America Interferon Sales YoY Growth (2015-2026)3.8 Middle East and Africa Interferon Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Interferon Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Interferon Sales YoY Growth (2015-2026) 4 Global Interferon by Application4.1 Interferon Segment by Application4.1.1 Hepatitis4.1.2 Multiple Sclerosis4.1.3 Others4.2 Global Interferon Sales by Application: 2015 VS 2020 VS 20264.3 Global Interferon Historic Sales by Application (2015-2020)4.4 Global Interferon Forecasted Sales by Application (2021-2026)4.5 Key Regions Interferon Market Size by Application4.5.1 North America Interferon by Application4.5.2 Europe Interferon by Application4.5.3 Asia-Pacific Interferon by Application4.5.4 Latin America Interferon by Application4.5.5 Middle East and Africa Interferon by Application 5 North America Interferon Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Interferon Sales Market Share by Country (2015-2020)5.1.2 North America Interferon Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Interferon Sales Market Share by Country (2021-2026)5.2.2 North America Interferon Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Interferon Market Size YoY Growth (2015-2026)5.3.2 Canada Interferon Market Size YoY Growth (2015-2026) 6 Europe Interferon Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Interferon Sales Market Share by Country (2015-2020)6.1.2 Europe Interferon Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Interferon Sales Market Share by Country (2021-2026)6.2.2 Europe Interferon Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Interferon Market Size YoY Growth (2015-2026)6.3.2 France Interferon Market Size YoY Growth (2015-2026)6.3.3 U.K. Interferon Market Size YoY Growth (2015-2026)6.3.4 Italy Interferon Market Size YoY Growth (2015-2026)6.3.5 Russia Interferon Market Size YoY Growth (2015-2026) 7 Asia-Pacific Interferon Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Interferon Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Interferon Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Interferon Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Interferon Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Interferon Market Size YoY Growth (2015-2026)7.3.2 Japan Interferon Market Size YoY Growth (2015-2026)7.3.3 South Korea Interferon Market Size YoY Growth (2015-2026)7.3.4 India Interferon Market Size YoY Growth (2015-2026)7.3.5 Australia Interferon Market Size YoY Growth (2015-2026)7.3.6 Taiwan Interferon Market Size YoY Growth (2015-2026)7.3.7 Indonesia Interferon Market Size YoY Growth (2015-2026)7.3.8 Thailand Interferon Market Size YoY Growth (2015-2026)7.3.9 Malaysia Interferon Market Size YoY Growth (2015-2026)7.3.10 Philippines Interferon Market Size YoY Growth (2015-2026)7.3.11 Vietnam Interferon Market Size YoY Growth (2015-2026) 8 Latin America Interferon Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Interferon Sales Market Share by Country (2015-2020)8.1.2 Latin America Interferon Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Interferon Sales Market Share by Country (2021-2026)8.2.2 Latin America Interferon Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Interferon Market Size YoY Growth (2015-2026)8.3.2 Brazil Interferon Market Size YoY Growth (2015-2026)8.3.3 Argentina Interferon Market Size YoY Growth (2015-2026) 9 Middle East and Africa Interferon Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Interferon Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Interferon Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Interferon Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Interferon Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Interferon Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Interferon Market Size YoY Growth (2015-2026)9.3.3 UAE Interferon Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Interferon Business10.1 Roche10.1.1 Roche Corporation Information10.1.2 Roche Description, Business Overview and Total Revenue10.1.3 Roche Interferon Sales, Revenue and Gross Margin (2015-2020)10.1.4 Roche Interferon Products Offered10.1.5 Roche Recent Development10.2 Anke Biotechnology10.2.1 Anke Biotechnology Corporation Information10.2.2 Anke Biotechnology Description, Business Overview and Total Revenue10.2.3 Anke Biotechnology Interferon Sales, Revenue and Gross Margin (2015-2020)10.2.4 Roche Interferon Products Offered10.2.5 Anke Biotechnology Recent Development10.3 Bayer10.3.1 Bayer Corporation Information10.3.2 Bayer Description, Business Overview and Total Revenue10.3.3 Bayer Interferon Sales, Revenue and Gross Margin (2015-2020)10.3.4 Bayer Interferon Products Offered10.3.5 Bayer Recent Development10.4 Merck & Co10.4.1 Merck & Co Corporation Information10.4.2 Merck & Co Description, Business Overview and Total Revenue10.4.3 Merck & Co Interferon Sales, Revenue and Gross Margin (2015-2020)10.4.4 Merck & Co Interferon Products Offered10.4.5 Merck & Co Recent Development10.5 Tri-Prime10.5.1 Tri-Prime Corporation Information10.5.2 Tri-Prime Description, Business Overview and Total Revenue10.5.3 Tri-Prime Interferon Sales, Revenue and Gross Margin (2015-2020)10.5.4 Tri-Prime Interferon Products Offered10.5.5 Tri-Prime Recent Development10.6 Kawin10.6.1 Kawin Corporation Information10.6.2 Kawin Description, Business Overview and Total Revenue10.6.3 Kawin Interferon Sales, Revenue and Gross Margin (2015-2020)10.6.4 Kawin Interferon Products Offered10.6.5 Kawin Recent Development10.7 Genzon Pharma10.7.1 Genzon Pharma Corporation Information10.7.2 Genzon Pharma Description, Business Overview and Total Revenue10.7.3 Genzon Pharma Interferon Sales, Revenue and Gross Margin (2015-2020)10.7.4 Genzon Pharma Interferon Products Offered10.7.5 Genzon Pharma Recent Development10.8 Novartis10.8.1 Novartis Corporation Information10.8.2 Novartis Description, Business Overview and Total Revenue10.8.3 Novartis Interferon Sales, Revenue and Gross Margin (2015-2020)10.8.4 Novartis Interferon Products Offered10.8.5 Novartis Recent Development10.9 Biogen10.9.1 Biogen Corporation Information10.9.2 Biogen Description, Business Overview and Total Revenue10.9.3 Biogen Interferon Sales, Revenue and Gross Margin (2015-2020)10.9.4 Biogen Interferon Products Offered10.9.5 Biogen Recent Development10.10 Merck KGaA10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Interferon Product Category, Application and Specification10.10.3 Merck KGaA Interferon Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Merck KGaA Recent Development10.11 Zydus Cadila10.11.1 Zydus Cadila Corporation Information10.11.2 Zydus Cadila Description, Business Overview and Total Revenue10.11.3 Zydus Cadila Interferon Sales, Revenue and Gross Margin (2015-2020)10.11.4 Zydus Cadila Interferon Products Offered10.11.5 Zydus Cadila Recent Development10.12 Huaxin Biotechnology10.12.1 Huaxin Biotechnology Corporation Information10.12.2 Huaxin Biotechnology Description, Business Overview and Total Revenue10.12.3 Huaxin Biotechnology Interferon Sales, Revenue and Gross Margin (2015-2020)10.12.4 Huaxin Biotechnology Interferon Products Offered10.12.5 Huaxin Biotechnology Recent Development10.13 Harbin Pharmaceutical10.13.1 Harbin Pharmaceutical Corporation Information10.13.2 Harbin Pharmaceutical Description, Business Overview and Total Revenue10.13.3 Harbin Pharmaceutical Interferon Sales, Revenue and Gross Margin (2015-2020)10.13.4 Harbin Pharmaceutical Interferon Products Offered10.13.5 Harbin Pharmaceutical Recent Development 11 Interferon Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Interferon Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Interferon Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See original here:
Interferon Market Growth, Projections, Analysis, Trends and Forecast 2026 | ( Roche, Anke Biotechnology, Bayer) - The Daily Chronicle

Read More...

We Analyzed the Future Direction of Vir Biotechnology Inc. (VIR), Here is What We Found – The News Heater

October 4th, 2020 11:00 am

Vir Biotechnology Inc. (NASDAQ:VIR) went down by -9.01% from its latest closing price compared to the recent 1-year high of $75.00. The companys stock price has collected 2.69% of gains in the last five trading sessions. Press Release reported on 09/24/20 that Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

Opinions of the stock are interesting as 4 analysts out of 7 who provided ratings for Vir Biotechnology Inc. declared the stock was a buy, while 0 rated the stock as overweight, 2 rated it as hold, and 0 as sell.

The average price from analysts is $50.67, which is $17.34 above the current price. VIR currently public float of 109.06M and currently shorts hold a 4.67% ratio of that float. Today, the average trading volume of VIR was 1.18M shares.

VIR stocks went up by 2.69% for the week, with a monthly drop of -15.19% and a quarterly performance of -13.31%. The volatility ratio for the week stands at 9.00% while the volatility levels for the past 30 days are set at 10.19% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is 6.75% for VIR stocks with a simple moving average of 3.21% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with Goldman repeating the rating for VIR by listing it as a Buy. The predicted price for VIR in the upcoming period, according to Goldman is $54 based on the research report published on September 14th of the current year 2020.

JP Morgan, on the other hand, stated in their research note that they expect to see VIR reach a price target of $29. The rating they have provided for VIR stocks is Neutral according to the report published on September 11th, 2020.

Needham gave a rating of Buy to VIR, setting the target price at $62 in the report published on August 20th of the current year.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.23% of loss for the given period.

Volatility was left at 10.19%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares surge +1.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.16% lower at present.

During the last 5 trading sessions, VIR rose by +2.69%, which changed the moving average for the period of 200-days by +151.32% in comparison to the 20-day moving average, which settled at $32.18. In addition, Vir Biotechnology Inc. saw 173.00% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at VIR starting from Virgin Herbert, who sale 3,805 shares at the price of $31.71 back on Sep 22. After this action, Virgin Herbert now owns 20,000 shares of Vir Biotechnology Inc., valued at $120,638 using the latest closing price.

Pang Phillip, the Chief Medical Officer of Vir Biotechnology Inc., sale 12,500 shares at $31.90 during a trade that took place back on Sep 16, which means that Pang Phillip is holding 29,777 shares at $398,694 based on the most recent closing price.

Current profitability levels for the company are sitting at:

The net margin for Vir Biotechnology Inc. stands at -2158.98. The total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return is now at value -81.10, with -42.30 for asset returns.

Based on Vir Biotechnology Inc. (VIR), the companys capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27. Total debt to assets is 0.22, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.21.

When we switch over and look at the enterrpise to sales, we see a ratio of 119.29, with the companys debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.81.

Read more:
We Analyzed the Future Direction of Vir Biotechnology Inc. (VIR), Here is What We Found - The News Heater

Read More...

Is Abeona Therapeutics Inc (ABEO) The Right Choice in Biotechnology? – InvestorsObserver

October 4th, 2020 11:00 am

A rating of 34 puts Abeona Therapeutics Inc (ABEO) near the middle of the Biotechnology industry according to InvestorsObserver. Abeona Therapeutics Inc's score of 34 means it scores higher than 34% of stocks in the industry. Abeona Therapeutics Inc also received an overall rating of 40, putting it above 40% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Abeona Therapeutics Inc (ABEO) stock is unmoved -0.48% while the S&P 500 is lower by -1.28% as of 11:06 AM on Friday, Oct 2. ABEO is flat $0.00 from the previous closing price of $1.05 on volume of 1,099,195 shares. Over the past year the S&P 500 has gained 14.67% while ABEO is lower by -53.54%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

Excerpt from:
Is Abeona Therapeutics Inc (ABEO) The Right Choice in Biotechnology? - InvestorsObserver

Read More...

Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering…

October 4th, 2020 10:57 am

DUBLIN, Sept. 30, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

In Global Regenerative Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking2.1. Introduction2.2. Regenerative Medicine partnering over the years2.3. Most active Regenerative Medicine dealmakers2.4. Regenerative Medicine partnering by deal type2.5. Regenerative Medicine partnering by therapy area2.6. Deal terms for Regenerative Medicine partnering2.6.1 Regenerative Medicine partnering headline values2.6.2 Regenerative Medicine deal upfront payments72.6.3 Regenerative Medicine deal milestone payments2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals3.1. Introduction3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers4.1. Introduction4.2. Most active Regenerative Medicine dealmakers4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory5.1. Introduction5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

AppendicesAppendix 1 - Regenerative Medicine deals by company A-ZAppendix 2 - Regenerative Medicine deals by stage of developmentAppendix 3 - Regenerative Medicine deals by deal typeAppendix 4 - Regenerative Medicine deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/dcq9uu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View original post here:
Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering...

Read More...

3 new degrees approved, including Ph.D. in regenerative medicine – IU Newsroom

October 4th, 2020 10:57 am

The Indiana University Board of Trustees has approved three new degrees, including a doctorate in the medical field and a master's in the accounting field.

During its meeting Oct. 1, the trustees supported three proposed degrees:

Regenerative medicine is a field that involves replacing or regenerating human cells, tissues or organs to establish, restore or enhance normal function.

The Ph.D. program in regenerative medicine and technologies will be offered by the Indiana Center for Regenerative Medicine and Engineering and the Department of Surgery at the IU School of Medicine. The program, open to practicing medical doctors, will provide an avenue for cutting-edge research that can be used in new ways to treat patients.

Before this approval, IU had no graduate-level programs for students seeking a degree in regenerative medicine and technologies. The labor market demand for such graduates is considered strong, with jobs in biotechnology companies, academic laboratories, and medical device manufacturing and logistics companies.

Changes in the accounting field and large employers' expressed needs have prompted the development of a new Master of Science in accounting curriculum that will prepare students for the emerging data-focused professional services workplace. With the proliferation of data and analytics techniques applications in the business world, integrated accounting, data and analytics competencies are required for the best job placements.

The new Master of Science in accounting with data and analytics degree will be offered by the Kelley School of Business. It will replace the current, traditional Master of Science in accounting degree as the residential offering on the Bloomington campus. The traditional Master of Science in accounting will continue to be offered through the Kelley School's online programs and will target "career switchers."

Students who seek the flexibility of an online format, have an interest in studying the foundations of sustainability and want to apply that knowledge to complex socio-environmental problems can find that opportunity in a new offering at IU Northwest, through the College of Arts and Sciences. The Bachelor of Arts in sustainability studies is a collaborative online degree, and was previously approved at IUPUI, IU East, IU Kokomo, IU South Bend and IU Southeast.

Regional demand for energy and sustainability specialists and the demand for "green" jobs are expected to grow over the next 10 years. Graduates with the degree could find jobs such as an energy analyst, environmental health and safety specialist, or an occupational health and safety technician.

The degrees approved by IU's trustees still await final approval by the Indiana Commission for Higher Education.

Read the rest here:
3 new degrees approved, including Ph.D. in regenerative medicine - IU Newsroom

Read More...

Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic…

October 4th, 2020 10:57 am

Aimed at offering Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) report readers with updated information as well as market relevant cues to leverage uninhibited growth in the Global Regenerative Medicine market, this intricately researched, designed, and articulated real-time reference of the market is a culmination of in-depth research mettle and best in class primary and secondary research initiatives that collectively influence a favorable growth trajectory in the Global Regenerative Medicine market.

In continuation with all the above market specific information furnished above, the report further in its subsequent sections also throws light upon other additional yet pertinent details that further channelize revenue generation in the Global Regenerative Medicine market. The report highlights massively the core growth propellants such as market driving factors, prevailing challenges and the like that tend to have a negative growth impact on the global Global Regenerative Medicine market.

Request a sample of Global Regenerative Medicine Market report @ https://www.orbisresearch.com/contacts/request-sample/4707408

Key Manufacturers Analysis:

Novartis AGMedtronic PlcBristol Myers Squibb (Celgene Corporation)Smith+Nephew (Osiris Therapeutics, Inc.)

Global Regenerative Medicine market Segmentation by Type:

Type IType IIType III

Global Regenerative Medicine market Segmentation by Application:

Application IApplication IIApplication III

Access full report @ https://www.orbisresearch.com/reports/index/global-regenerative-medicine-market-size-and-forecast-with-impact-analysis-of-covid-19-2020-2024

Various other dynamics of the Global Regenerative Medicine market pertaining to the growth prospects have been mentioned and well elaborated in the course of the report documentation thus ushering a novel perspective for the players to instrument growth propelling business decisions, defying stringent competition in the Global Regenerative Medicine market. Based on a thorough analytical review leading players comprising both established and new market aspirants in the Global Regenerative Medicine market can have a thorough understanding about the market and subsequently chalk out elaborate plans to steer remunerative returns in the aforementioned Global Regenerative Medicine market.

Key Regions:

North AmericaEuropeAsia PacificROW

All the mentioned updates about the Global Regenerative Medicine market specified in the report have been derived post a dedicated research initiative comprising primary and secondary research practices. Proceeding into unraveling new developments in the report pertaining to the Global Regenerative Medicine market, the report is committed to offer a decisive, problem solving approach based on which readers are encouraged to unravel the various discerning factors and inputs that collectively orchestrate an optimistic growth trail in the discussed Global Regenerative Medicine market.

Ready-to refer Market Insider Reports: Top Reason to Buy the Report

1. A team of expert research veterans, practicing best in industry roles to derive real time developments in the Global Regenerative Medicine market, affecting growth.2. Systematic segment-wise analysis to identify growth reckoning segment.3. A thorough historical study to decode future growth trajectory.4. Rear view analysis of opportunity landscape and barrier analysis and threat identification.5. Astute analysis of the competition spectrum to identify market leaders and their growth favoring business tactics.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4707408

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Excerpt from:
Global Regenerative Medicine Market 2020 Growth Analysis, Trends, COVID-19 Analysis and Forecast to 2024, Key Manufacturers- Novartis AG, Medtronic...

Read More...

Remember how urgent it was to support embryonic stem cell research? That was then; this is now – BioEdge

October 4th, 2020 10:57 am

Remember how urgent it was to support embryonic stem cell research? That was then; this is now

The hot button bioethical issue of 2004 was embryonic stem cell research. Supporters spoke of life-saving cures and dismissed ethical misgivings. Surfing a wave of hope, Californian voters voted for a US$3 billion bond issue to establish the California Institute for Regenerative Medicine.

Sixteen years later, the CIRM has almost run out of money and its backers are rattling the tin in the hope that voters will approve a $5.5 billion bond issue to support its research.

Some of the states major newspapers have editorialised against it. With many of its critics, they contend that the CIRM has not delivered on its miracle cures, that its governance has been poor and that there was too much potential for conflict of interest.

The Los Angeles Times decried the earlier over-sell:

[The CIRM] hasnt yet yielded a significant financial return on investment for the state or the cures that were ballyhooed at the time. Though no one ever promised quick medical miracles, campaign ads strongly implied they were around the corner if only the funding came through. Proponents oversold the initiatives and voters cant be blamed if they view this new proposal with skepticism.

The San Francisco Chronicle, which exposed some of the CIRMs deficiencies in a 2018 expos, criticised the way its funds had been spent:

More than half the original funding went to buildings and other infrastructure, education and training, and the sort of basic research that, while scientifically valuable, is a long way from medical application. Theres nothing inherently wrong with that, but it is at odds with the vision of dramatic advancements put to voters."

Michael Cook is editor of BioEdge

Read the rest here:
Remember how urgent it was to support embryonic stem cell research? That was then; this is now - BioEdge

Read More...

What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) – KQED

October 4th, 2020 10:57 am

Olivia Allen-Price [00:01:55] OK, so what exactly does this bond fund?

Danielle Venton [00:01:59] This would fund $5.5 billion in stem cell research and treatments in California. Some of the diseases that stem cell research is seeking to cure or treat include cancer, Alzheimer's disease, diabetes, spinal cord injuries, blindness, and even COVID-19. I spoke recently with a guy named Jake Javier. He supports this bond initiative because he knows firsthand how life changing stem cell research can be.

Jake Javier [00:02:25] I am in my last year at Cal Poly.

Danielle Venton [00:02:28] So, Jake grew up locally in Danville and was just graduating high school when he suffered a life altering injury.

Jake Javier [00:02:35] On the last day of high school, I drove in to a pool and hit my head on the bottom and broke my neck and was immediately paralyzed.

Danielle Venton [00:02:47] He says his injury was complete, with very little hope of recovery. But a doctor at Stanford reached out to Jake and his family and said, you can be part of this clinical trial where we, with a one time surgery, will inject stem cells into the damaged area and you may possibly see some benefits.

Danielle Venton [00:03:07] Now, Jake is still injured.

Jake Javier [00:03:09] I'm a quadriplegic. I use a wheelchair.

Danielle Venton [00:03:11] But he says after the surgery, he noticed more movement in his arms, in his hands.

Jake Javier [00:03:17] So, I mean, with my injury, I'm at a level where I would normally not have any function at all in my hands and very, very little function like in my triceps and things like that. Muscles that are really important for functionality and, you know, being able to get through day to day activities that could help me push myself around more, help me transfer in and out of my chair independently. And then also, I notice, you know, I got some some finger movement. It doesn't seem like much, but even that little movement has helped me so much with picking things up and things like that. So it was really, I was really blessed to see that happen.

Danielle Venton [00:03:51] So he doesn't know how much of his recovery is due to the stem cells. How much is natural, or how much is due to physical therapy. But today he's able to live independently, to go to college and he wants to pursue a career in medicine. And he is a big believer in stem cell research, regenerative medicine, and is really hoping that California voters will support this proposition.

Olivia Allen-Price [00:04:20] Now, what exactly are stem cells and how do they work, I guess?

Danielle Venton [00:04:25] Yeah, stem cells are types of cells that can be turned into any type of specialized cell. Scientists have known about them since the eighteen hundreds, but it wasn't until the late 90s that researchers developed a method to derive them from human embryos and grow them in a laboratory. And then people really began to get excited about their potential for medicine. Now these cells came from unused embryos created for in vitro fertilization, and they were donated with informed consent. But many anti-abortion groups felt that using the cells were tantamount to taking a human life. So in 2001, then President George W. Bush banned federal funding for any research using newly created stem cell lines.

Olivia Allen-Price [00:05:09] OK. And how does that get us now to bonds in California?

Danielle Venton [00:05:13] Well, Californians wanted to circumvent these federal restrictions, and in 2004 voted for a bond that gave the state $3 billion to create a research agency called the California Institute of Regenerative Medicine, or CIRM. There was a lot of public support for it. And it just felt like these wonderful cures could be right around the corner. Celebrities like Michael J. Fox appeared in TV commercials.

Michael J. Fox TV commercial [00:05:36] My most important role lately is as an advocate for patients, and for finding new cures for diseases. That's why I'm asking you to vote yes on Proposition 71, Stem Cell Research Initiative.

Danielle Venton [00:05:48] And the money for that research, that $3 billion, has now run out. And to continue their work, the stem cell advocacy group, Americans for Cures, is asking voters for more money.

Olivia Allen-Price [00:06:00] So we're basically voting on whether we want to refill the stem cell research piggy bank here.

Danielle Venton [00:06:05] Yeah, exactly. Some question if the state can afford this at this time when budgets are going to be so tight. Others have been disappointed by the slow pace of cures coming out of the field. Now, there are people who credit this research, such as Jake, with improving or restoring their health or the health of their loved ones. Or maybe they hope that one day it will, and they would balk at the idea that this is not worthy research. They point to achievements that the agency has funded. That includes effectively a cure for bubble baby disease. This is when someone is born without a functioning immune system. That mutation can now be corrected with genetically modified stem cells. And recently, just within the last year or so, the FDA approved two new treatments for blood cancer, developed with CIRM support. These achievements are what the agency points to when they're criticized for not having accomplished more. And they say the process of scientific discovery is long and unpredictable.

Olivia Allen-Price [00:07:04] Now, wasn't that Bush-era ban on stem cell research that you were talking about earlier wasn't that overturned?

Danielle Venton [00:07:11] Yes, that was overturned by President Obama. However, there are current members of Congress who are lobbying President Trump to ban the research again. And if that happens, then California would be the only major player in stemcell research once again in the United States.

Olivia Allen-Price [00:07:30] All right, so who is supporting Prop 14?

Danielle Venton [00:07:32] Governor Gavin Newsom, for one. Many patient advocacy organizations and medical and research institutions, including the California Board of Regents. These people don't want to see the pace of this research slow. They want it to accelerate. The political action committee supporting this proposition is reporting more than six million dollars in contributions.

Olivia Allen-Price [00:07:53] All right. And what about the opposition? Who's against it?

Danielle Venton [00:07:55] Well, so far, there's no organized, funded opposition. There have been several newspaper editorials coming out against it, including locally, the Mercury News and the Santa Rosa Press Democrat. They basically say state bonds aren't the way to fund research and the situation isn't like it was in 2004 and that the institute should now seek other sources of funding and move forward as a nonprofit.

Olivia Allen-Price [00:08:19] All right, Danielle. Well, thanks, as always for your help.

Danielle Venton [00:08:21] My pleasure. Thanks.

Olivia Allen-Price [00:08:28] In a nutshell, a vote yes on Proposition 14 says you think Californians should give $5.5 billion to the state's stem cell research institute. That money will be raised by selling bonds, which the state would pay back, with interest, out ofthe general fund over the next 30 years. A vote no means you think we shouldn't spend public money on this research.

Olivia Allen-Price [00:08:54] That's it on Proposition 14. We'll be back tomorrow with an episode on Prop 15. And oh, it is a doozy. Commercial property tax! A partial rollback of one of California's most controversial propositions! It's going to be fire. In the meantime, you can find more of KQED election coverage at KQED.org/elections. Two reminders on the way out: October 19th is the last day to register to vote and mail in ballots must be postmarked on or before November 3rd.

Olivia Allen-Price [00:09:28] Bay Curious is made in San Francisco at member supported KQED. I'm Olivia Allen-Price. See you tomorrow.

Follow this link:
What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED

Read More...

Regenerative Medicine Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 – The Daily Chronicle

October 4th, 2020 10:57 am

Fort Collins, Colorado The Regenerative Medicine Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The Regenerative Medicine Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the Regenerative Medicine Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global Regenerative Medicine Market valued approximately USD 49.68 billion in 2018 is anticipated to grow with a healthy growth rate of more than 24.2% over the forecast period 2019-2026.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=28424

Industry Regenerative Medicine Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=28424

The report provides comprehensive data on the Regenerative Medicine market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Regenerative Medicine Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Regenerative Medicine market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

By Technology:

By Application:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=28424

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Regenerative Medicine Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-regenerative-medicine-market-size-study/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View original post here:
Regenerative Medicine Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

Read More...

Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 – Crypto Daily

October 4th, 2020 10:57 am

According to IMARC Groups latest report, titled Regenerative Medicine Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,. Looking forward, IMARC Group expects the global regenerative medicine market to continue its strong growth during the next five years.

Regenerative medicine refers to a field of biomedical sciences involved in restoring the structure and function of damaged cells, organs, and tissues. It includes the study of stem cells that are developed in laboratories and then safely inserted into the human body to regenerate damaged bones, cartilage, blood vessels, and organs. Cellular and acellular regenerative medicines are widely adopted in various clinical therapeutic procedures, including cell therapies, immunomodulation, and tissue engineering. They have the potential to treat various chronic diseases, including Alzheimers, Parkinsons, cardiovascular disorders (CVDs), osteoporosis, spinal cord injuries, etc.

Request for a free sample copy of this report: https://www.imarcgroup.com/regenerative-medicine-market/requestsample

Market Trends

The rising prevalence of chronic diseases and genetic disorders is primarily driving the demand for regenerative medicine across the globe. Moreover, the growing geriatric population who are more prone to musculoskeletal, dermatological, and cardiological disorders is also augmenting the need for regenerative medicines. Furthermore, several technological advancements in cell-based therapies have led to the adoption of 3D bioprinting techniques and artificial intelligence (AI), thereby further propelling the market for regenerative medicine. Moreover, regenerative medicine decreases the risk of organ rejection by the body post-transplant and increases the patients recovery speed, thereby gaining traction in numerous organ transplantation procedures. The increasing investments in extensive R&D activities in the field of medical sciences are expected to drive the market for regenerative medicine.

Regenerative Medicine Market 2020-2025 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

The report has segmented the market on the basis of type, application, end user and region.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Explore full report with table of contents: https://bit.ly/2RAf08Y

Breakup by Region:

Key highlights of the report:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US:IMARC Group30 N Gould St, Ste RSheridan, WY 82801, USAWebsite: https://www.imarcgroup.com/Email: [emailprotected]USA: +1-631-791-1145Follow us on twitter: @imarcglobalLinkedin: https://www.linkedin.com/company/imarc-group

See the rest here:
Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 - Crypto Daily

Read More...

FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin – Business Wire

October 4th, 2020 10:57 am

MIAMI--(BUSINESS WIRE)--Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19.

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease. Aside from Convalescent Plasma, Zofin, is the first reported acellular therapy which can be accessed under FDAs approved expanded access program. Zofin is manufactured to retain naturally occurring microRNAs, without the addition of any other substance or diluent.

This recent FDA approval follows the treatment of six outpatients treated under emergency INDs, who have reported significant improvement after being treated with Zofin. Organicell is currently in the process of enrolling moderate to severe COVID-19 patients for a Phase I/II placebo controlled clinical trial (NCT04384445) to evaluate the safety and potential efficacy of Zofin.

Treating patients in an outpatient setting may be critical in helping to prevent the progression of the disease and further hospitalization which could lessen the impact on hospitals, thereby reducing medical costs, said Albert Mitrani, Chief Executive Officer of Organicell.

About Organicell Regenerative Medicine, Inc.:

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of nanoparticles to develop innovative biological therapeutics for the treatment of degenerative diseases. The companys proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Maria Ines Mitrani, Chief Science Officer. To learn more, please visit https://organicell.com/.

About Zofin:

Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin for the treatment of moderate to SARS related to COVID-19 infection vs placebo.

Forward-Looking Statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the Securities Act), the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as will, believes, expects, potential or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Visit link:
FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin - Business Wire

Read More...

FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration – PRNewswire

October 4th, 2020 10:57 am

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs has entered into a clinical collaboration agreement with Brazilian R4D Biotech.Holding the world's largest patent portfolio in the field of cell therapies using fibroblasts, FibroGenesis is expanding its ongoing clinical programs internationally. The partnership will pave the way for clinical studies of PneumoBlast in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval by the FDA.

Administration of PneumoBlast in pre-clinical and animal studies resulted in dramatic improvement of immunological signaling molecules, reducing concentrations of the inflammatory cytokines interleukin-1 beta, interleukin-6, interleukin-8, interleukin-17, interleukin-18, and Tumor Necrosis Factor alpha TNFa. Company scientists have also demonstrated that PneumoBlast has induced statistically significant reduction of lung fibrosis and lung scarring in COVID-19 infected animals, particularly when compared to more conventional treatments using bone marrow derived mesenchymal stem cells (BMSCs). Furthermore, recent data supports the potential benefits of PneumoBlast for preventing COVID-19 blood clotting. Both companies will collaborate on a clinical study design that meets the needs of Brazilian patients.

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against this virus," commented Pete O'Heeron, Chief Executive Officer, FibroGenesis. "The collaboration with R4D Biotech is another strategic milestone that emphasizes our commitment to expand fibroblast research globally."

"The lab results which indicate our cell therapy approach possesses both therapeutic effects on animal models of the acute stage of COVID-19, and also benefits a cure for residual pathology seen in COVID-19 patients, has our research team extremely excited," said Thomas Ichim, Ph.D., Chief Scientific Officer, FibroGenesis.

"Technology transfer is at the core of this partnership," said Paulo Ferraz, BRICS/Emerging Markets Director of international fund Newstar Ventures and an advisor for FibroGenesis on this transaction. "R4D Biotech has access to sophisticated resources comprising research facilities and hospitals, and its talent pool includes scientific advisors who are recognized academics and distinguished members of the Brazilian Academy of Pharmaceutical Sciences. PneumoBlast clinical study will represent the first step in a long-term relationship designed to aid in the discovery of advanced therapeutic solutions for chronic medical needs."

About R4D Biotech:R4D Biotech is a Brazilian emerging company headquartered in the state of So Paulo focused on research and development for biotechnology and healthcare, with the mission of bringing disruptive technology innovation across all steps of clinical development in life sciences.

About FibroGenesis:Based in Houston, Texas, FibroGenesis is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 240+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.Visit http://www.Fibro-Genesis.com.

SOURCE FibroGenesis

http://www.Fibro-Genesis.com

Read more:
FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration - PRNewswire

Read More...

Page 351«..1020..350351352353..360370..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick